Instituto de Salud Carlos III -ko ikertzaileekin lankidetzan egindako argitalpenak (9)

2024

  1. Caspases compromise SLU7 and UPF1 stability and NMD activity during hepatocarcinogenesis

    JHEP Reports, Vol. 6, Núm. 8

2023

  1. Frontiers in fatty liver: recent advances in pathogenic mechanisms, assessment of patients’ prognosis and pharmacotherapy: MASLD: new pathogenic mechanisms, risk assessment tools and drug therapies

    Journal of Physiology and Biochemistry

  2. Loss of liver function in chronic liver disease: An identity crisis

    Journal of Hepatology, Vol. 78, Núm. 2, pp. 401-414

2022

  1. Impact of CYLD on chromatin structure and histone methylation in malignant melanoma

    International Journal of Molecular Medicine, Vol. 49, Núm. 5

  2. New molecular mechanisms in cholangiocarcinoma: signals triggering interleukin-6 production in tumor cells and KRAS co-opted epigenetic mediators driving metabolic reprogramming

    Journal of Experimental and Clinical Cancer Research, Vol. 41, Núm. 1

2021

  1. FOSL1 promotes cholangiocarcinoma via transcriptional effectors that could be therapeutically targeted

    Journal of Hepatology, Vol. 75, Núm. 2, pp. 363-376

  2. The splicing regulator SLU7 is required to preserve DNMT1 protein stability and DNA methylation

    Nucleic Acids Research, Vol. 49, Núm. 15, pp. 8592-8609

2018

  1. Fibroblast growth factors 19 and 21 in acute liver damage

    Annals of Translational Medicine, Vol. 6, Núm. 12, pp. 257

2016

  1. Chromatin Remodeling and Epigenetic Reprogramming in Chronic Disease and Cancer in the Liver and Pancreas

    Chromatin Signaling and Diseases (Elsevier Inc.), pp. 365-385